statistiche ricercatore

Continente	#
NA - Nord America	539
AS - Asia	352
EU - Europa	337
SA - Sud America	73
AF - Africa	16
Continente sconosciuto - Info sul continente non disponibili	1
OC - Oceania	1
Totale	1.319

Nazione	#
US - Stati Uniti d'America	519
SG - Singapore	172
IT - Italia	77
CN - Cina	70
SE - Svezia	64
BR - Brasile	59
FR - Francia	48
DE - Germania	35
VN - Vietnam	30
IE - Irlanda	24
FI - Finlandia	23
GB - Regno Unito	16
IN - India	15
CA - Canada	14
ID - Indonesia	13
PL - Polonia	10
AT - Austria	8
ES - Italia	8
HK - Hong Kong	8
JP - Giappone	8
RU - Federazione Russa	8
AR - Argentina	7
BD - Bangladesh	7
ZA - Sudafrica	7
PK - Pakistan	6
TR - Turchia	6
CI - Costa d'Avorio	4
MA - Marocco	4
UZ - Uzbekistan	4
CO - Colombia	3
IR - Iran	3
VE - Venezuela	3
BE - Belgio	2
IQ - Iraq	2
KZ - Kazakistan	2
MX - Messico	2
NL - Olanda	2
A2 - ???statistics.table.value.countryCode.A2???	1
AL - Albania	1
AU - Australia	1
AZ - Azerbaigian	1
BY - Bielorussia	1
CH - Svizzera	1
CY - Cipro	1
CZ - Repubblica Ceca	1
DK - Danimarca	1
GL - Groenlandia	1
GR - Grecia	1
GT - Guatemala	1
IL - Israele	1
IM - Isola di Man	1
JM - Giamaica	1
JO - Giordania	1
KE - Kenya	1
LT - Lituania	1
MD - Moldavia	1
OM - Oman	1
PA - Panama	1
PE - Perù	1
RO - Romania	1
SK - Slovacchia (Repubblica Slovacca)	1
TW - Taiwan	1
UA - Ucraina	1
Totale	1.319

Nome	#
The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition	158
Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir–rilpivirine in clinical practice	152
Difference in the neurocognitive functions of WLWH and MLWH in an Italian cohort of people living with HIV	150
The University of California San Diego performance-based skills assessment: a useful tool to detect mild everyday functioning difficulties in HIV-infected patients with very good immunological condition	137
Short Communication: Comparing Lamivudine+Dolutegravir and Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategies: Preliminary Results from Clinical Practice	121
'How much raltegravir do you take?' The answer may not be so obvious: an accidental finding from clinical practice	118
Use of Long-Acting Therapies for HIV Care in Italy: Are People Living with HIV Prepared for Change? A Cross-Sectional Study	117
Evaluation of doravirine-based regimen population target in a large Italian clinical center	103
People Living with HIV in the COVID-19 Era: A Case Report	101
Real-Life Safety of Doravirine in Treatment-Experienced, Virologically Suppressed PLWHIV	96
Re: "No Significant Changes in Weight and Body Fat Mass in Suppressed HIV Infected Patients Switched to Dual Combination Lamivudine plus Dolutegravir or Raltegravir" by Calza et al	89
Totale	1.342

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	3	0	0	0	0	0	0	0	0	0	0	0	3
2021/2022	75	2	1	0	5	0	1	5	9	2	2	7	41
2022/2023	297	33	41	14	48	10	34	12	40	38	2	21	4
2023/2024	143	4	27	1	10	4	21	15	4	10	12	18	17
2024/2025	254	3	3	51	11	14	15	15	7	35	23	36	41
2025/2026	534	88	9	28	58	109	25	75	27	57	36	18	4
Totale													1.342

IRIS UniCatt